Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aurora Cannabis Inc (ACB) vs Eli Lilly And Co (LLY) Price & Performance

Aurora Cannabis IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Eli Lilly And Co — how do they compare? Aurora Cannabis Inc trades at $3.45 (market cap $178.92M), while Eli Lilly And Co trades at $1,214.52 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 6148× Aurora Cannabis Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.

ACBLLY
Market Cap
$178.92M$1.10T
Sector
HealthHealth
52-Week High
$6.23$1.24K
52-Week Low
$2.58$639.43
Enterprise Value
$123.48M$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aurora Cannabis Inc

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

Read more on ACB

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY